ENHANCEMENT OF LUMBAR FUSION W/ RHBMP 2/ COLLAGEN OR LMP

使用 RHBMP 2/胶原蛋白或 LMP 增强腰椎融合

• 批准号: 8357373
• 负责人: SCOTT D. BODEN
• 金额: $ 3.29万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357373
• 关键词: Animals; Bone Transplantation; Ceramics; Collagen; Complication; Cytoplasmic Granules; Dose; Failure; Funding; Genetic Engineering; Grant; Growth Factor; Healed; Human; Macaca mulatta; Modeling; National Center for Research Resources; Operative Surgical Procedures; Oryctolagus cuniculus; Osteogenesis; Preparation; Primates; Principal Investigator; Recombinants; Reporting; Research; Research Infrastructure; Resistance; Resources; Site; Source; Speed; Spinal Fusion; Testing; Titania; Titanium; United States National Institutes of Health; Vertebral column; bone; bone morphogenetic protein 2; cost; healing; minimally invasive; nonhuman primate

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Lumbar spinal fusion is commonly performed on humans, but the failure of bone union is a frequent complication. Osteoinductive growth factors synthesized by recombinant DNA technology have been shown to induce bone formation in heterotopic sites. Recombinant human BMP-2 (rhBMP-2) has been effective in generating spine fusions in a rabbit model. To determine the dose of the growth factor in humans, and to determine the speed of healing, a nonhuman primate model is used. In 2010, we did surgery on 4 rhesus monkeys to investigate a new ceramic bone graft substitute. Higher doses than expected were required to make bone in the primate. The growth factor was delivered inside a hollow titanium treated fusion cage through a minimally invasive approach. Studies have focused on fine tuning the dose and studying alternative carrier materials, including different combinations of ceramic materials for use in the posterolateral spine. We investigated new carriers for BMP-2 and continued studies with LMP-1, and we found that a compression resistant collagen matrix was an effective carrier. During the reporting period, we tested wrapping the existing BMP-w preparation around a ceramic granule matrix as a bulking agent. This was successful in 2/3s animals to achieve spine fusion. This will move on to human trials.

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 腰椎融合术是一种常见的人体手术，但骨愈合失败是一种常见的并发症。通过重组DNA技术合成的骨诱导生长因子已显示在异位部位诱导骨形成。重组人BMP-2（rhBMP-2）在兔模型中可有效实现脊柱融合。为了确定人类中生长因子的剂量，并确定愈合的速度，使用非人灵长类动物模型。2010年，我们对4只恒河猴进行了手术，以研究一种新的陶瓷骨移植替代物。灵长类动物需要比预期更高的剂量才能生成骨骼。通过微创方法将生长因子输送到中空钛处理的融合器内。研究集中在微调剂量和研究替代载体材料，包括用于后外侧脊柱的陶瓷材料的不同组合。我们研究了BMP-2的新载体，并继续研究LMP-1，我们发现抗压胶原基质是一种有效的载体。在报告期内，我们测试了将现有BMP-w制剂包裹在陶瓷颗粒基质周围作为填充剂。这在2/3s动物中成功实现脊柱融合。这将转移到人体试验。